4.360USD+6.34%Mkt Cap: 267.78M $P/E: —1d ago
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat live…
Industry Peers
Medical DevicesIndicators:|
Key Statistics
Company
Market Cap267.78M $
Enterprise Value229.74M $
Revenue (TTM)44.88M $
Gross Profit38.19M $
Net Income (TTM)-39.23M $
Revenue/Share1.024 USD
Last Price4.360 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees102
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-17.44
PEG—
EV/EBITDA-8.37
EV/Revenue5.12
P/S5.97
P/B20.86
EPS (TTM)-1.42
EPS (Forward)-0.25
52W Range
2.20038% of range7.950
52W High7.950 USD
52W Low2.200 USD
Profitability
Gross Margin84.57%
Oper. Margin-94.52%
EBITDA Margin-61.13%
Profit Margin-86.88%
ROE115.85%
ROA-111.03%
Growth
Revenue Growth-2.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-18.01M $
CapEx (TTM)918.00K $
FCF Margin-20.73%
FCF Yield-3.47%
Net Debt-22.07M $
Net Debt/EBITDA0.80
Balance Sheet
Debt/Equity-1.02
Current Ratio5.78
Quick Ratio5.24
Book Value/Sh0.2090 USD
Cash/Share0.9210 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)9.000 USD
Upside (mean)+106.4%
Target Range7.000 USD – 11.00 USD
$7.000+106.4% to mean$11.00
# Analysts4
Ownership
Shares Out.61.42M
Float49.34M
Insiders34.05%
Institutions34.59%
Short Interest
Short Ratio6.2d
Short % Float6.62%
Short % Out.5.02%
Shares Short3.08M
Short (prev mo.)2.10M
Technical
SMA 503.832 (+13.8%)
SMA 2004.795 (-9.1%)
Beta0.43
S&P 52W Chg20.25%
Avg Vol (30d)384.84K
Avg Vol (10d)280.35K
Technical Indicators
RSI (14)55.4
MACD0.0971
MACD Signal0.1338
MACD Hist.-0.0367
BB Upper4.782 USD
BB Middle4.260 USD
BB Lower3.738 USD
BB Width24.49%
ATR (14)0.3372 USD
Vol Ratio (20d)0.47x